<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361242</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PXT00864-04</org_study_id>
    <nct_id>NCT02361242</nct_id>
  </id_info>
  <brief_title>24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion</brief_title>
  <acronym>PLEODIAL-II</acronym>
  <official_title>24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharnext SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ascopharm Groupe Novasco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharnext SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PLEODIAL-II study is an extension of the previous pilot PLEODIAL-I study (CLN-PXT00864-03
      protocol) and is designed for the descriptive analysis of patients with mild AD who are
      exposed to PXT00864 over an additional 24-week period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients having completed the previous 12-week PLEODIAL-I study were eligible to receive
      PXT00864 in this 24-week open-label extension PLEODIAL-II study in order to collect some
      additional long-term data regarding the safety and the potential effect of PXT00864 on
      cognitive and behavioural impairments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the total score of the 11-items Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>V5 (study entry), V6 (after 12 weeks), V7 (after 24 weeks)</time_frame>
    <description>Scores on the ADAS-Cog range from 0 to 70 with higher scores indicating greater cognitive impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>throughout the 24-week study period</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>PXT00864 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 0.4 mg of acamprosate and 1 white capsule containing 6 mg of baclofen are taken orally b.i.d during 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT00864 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 1 mg of acamprosate and 1 white capsule containing 15 mg of baclofen are taken orally b.i.d during 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT00864 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 20 mg of acamprosate and 1 white capsule containing 12 mg of baclofen are taken orally b.i.d during 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT00864</intervention_name>
    <description>PXT00864 is a fixed-dose combination of baclofen and acamprosate</description>
    <arm_group_label>PXT00864 Dose 1</arm_group_label>
    <arm_group_label>PXT00864 Dose 2</arm_group_label>
    <arm_group_label>PXT00864 Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Mild Alzheimer's Disease patient who was included in PLEODIAL-I study

          -  Mini Mental State Examination (MMSE) score greater or equal to 20

        Main Exclusion Criteria:

          -  Patient who was not compliant with the previous PLEODIAL-I study protocol

          -  Patient who experienced significant adverse events which necessitated treatment
             discontinuation during the PLEODIAL-I study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Orgogozo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Pellegrin, Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMRR</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PXT00864</keyword>
  <keyword>mild AD</keyword>
  <keyword>phase 2a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

